Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

How the mighty have fallen. Roughly 10 years ago, Walgreens Boots Alliance Inc (NASDAQ:WBA) was knocking on the door of $100, a promising blue-chip pharmacy stock. As 2024 winds down, Walgreens stock has been booted from the Dow and holds the (dis)honor of worst-performing stock on the S&P 500 Index (SPX).

Year in Review: The Worst-Performing SPX Stock of 2024

It's been a tough year for Walgreens Boots Alliance (WBA -1.18%) stock, which is trading down nearly 65% year to date, as of this writing. Things don't look any better when looking even further out, as the stock has lost 88% of its value over the past decade.

Is Walgreens Stock a Buy?

Cintas Corp

DoorDash

Dropbox

Gilead Sciences

Intuit

Samsara

Cloudflare

UiPath

Taiwan Semiconductor Manufacturing

Unity Software

Subscribers to  Chart of the Week  received this commentary on Sunday, December 8.

8 Trading Lessons to Take From Our 2024 Stock Picks

Until recently, many Walgreens Boots Alliance (WBA -2.62%) investors were desperately hungry for good news to boost the company's languishing stock price. On Dec. 10 they got some, in the form of a news report detailing a potential buyout deal.

Walgreens Could Be About to Make a Major Move That Has Investors Thrilled

PennantPark Floating Rate Capital

Income-seeking investors looking for ultra-high-yield dividend stocks can find what they're looking for in the healthcare and finance sectors. Walgreens Boots Alliance (WBA 2.14%) and PennantPark Floating Rate Capital (PFLT -0.28%) offer yields above 10% at recent prices.

2 Dividend Stocks Yielding More Than 10%. Are They Right for Your Passive Income Portfolio?

CVS Health

Legislation slowly wending its way through states and in Washington could mean increased payments to drugstore chains like CVS Health, Walgreens, Walmart and independent pharmacies across the country.

Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens

Ford Motor Company

Altria

"Dogs of the Dow" is a popular investing strategy. By buying shares of the highest-yielding stocks on the Dow Jones Industrial Average (^DJI 1.38%) market index, you can buy into top-quality companies whose shares are selling at a discount.

Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?

I am downgrading Walgreens Boots Alliance from a buy to a hold due to balanced risks and less compelling valuation. Despite a 10% gain since my September buy call, new fundamental developments and tepid M&A trends warrant a cautious stance. WBA's Q4 results beat expectations, but a soft FY 2025 guide, store closures, and ongoing sales pressures pose significant risks.

Walgreens' Rally Sputters Amid Takeover Chatter (Rating Downgrade)

Walgreens Boots Alliance (WBA -0.80%) stock looks to have finally received some much-needed bullishness from investors. The stock was jumping last week on rumors that a private equity firm may be buying the company.

Walgreens Boots Alliance Stock Jumps on Report of a Possible Buyout. Here's Why Investors Should Tread Carefully.

BLOOMINGTON, Minn. and ATLANTA , Dec. 18, 2024 /PRNewswire/ -- CaringBridge, a nonprofit health platform, and Walgreens, an integrated healthcare, pharmacy and retail leader, are proud to announce a two-day campaign when Walgreens will match donations on CaringBridge up to $50,000 on December 17 and 18.

CaringBridge and Walgreens Announce $50,000 Donation Match on www.CaringBridge.org to Support Family Caregivers

Boot Barn Hlds

Etsy

MarineMax

Intel

Photronics

With the S&P 500 Small-Cap Stock Index (SML) underperforming the S&P 500 Large-Cap Index (SPX) by -2.49% in December as of Monday's market close, now is the time to make some of your most important stock purchase decisions. That's because January and the storied “January Effect” are approaching.

6 Stocks To Consider Buying Before Year-End

Crown Castle International

LyondellBasell Industries

Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and offer a promising avenue for total return.

Last Call for 2024 Rate Cuts: Grab These 6% and Higher Yielding S&P 500 Stocks Now

Agree Realty

Essential Properties Realty Trust Inc

Gaming and Leisure Properties

CarMax

Kroger

Lowe's

Realty Income Corp

PepsiCo

Starwood Property

Tractor Supply

Visa

Vici Properties

Walmart

Agree Realty and VICI Properties are high-quality REITs with strong fundamentals and impressive total returns, but currently offer little margin of safety due to their run-up in share prices. Investing with a margin of safety helps manage market volatility; for example, my cost basis of $53 for Realty Income has helped me stomach volatility and the stock's underperformance. I recommend assigning stocks specific roles in your portfolio; for example, Starwood Property for stable dividends, PepsiCo for moderate growth, and Visa for high growth, balancing income and growth.

2 REITs To Add To Your Christmas List And When To Buy For A Margin Of Safety

AGNC Investment

Icahn Enterprises

If you're in the market for dividend-paying stocks, you're onto a smart investing strategy. That's because shares of healthy and growing dividend-paying companies are likely to rise in value over time, and their dividend payouts will tend to do the same.

Should You Buy 3 of the Highest-Paying Dividend Stocks in the Nasdaq?

Walgreens Boots Alliance (WBA 6.78%) is a household name in the healthcare industry. Consumers in America and worldwide have frequented their neighborhood pharmacies for generations.

Is Walgreens Boots Alliance a Millionaire Maker?

With its shares falling more than 80% over the last three years alone, investors are likely eager for a major shakeup in the way that Walgreens Boots Alliance (WBA 6.78%) does business. If the rumors are to be believed, that shakeup could be coming very soon, and it would affect every shareholder.

Does This Rumor Make Walgreens Boots Alliance Stock a Buy?

DEERFIELD, Ill.--(BUSINESS WIRE)--With a history of more than 120 years serving communities across the country, Walgreens prides itself in being a trusted retail pharmacy partner for more than 9 million patients and customers it serves each day. Walgreens is amplifying its commitment to its patients and partners through the formation of the Walgreens Clinical Trials Patient Advisory Board. Since its launch in June 2022, the Walgreens Clinical Trials team has reached more than 7 million patients.

Walgreens Launches Inaugural Patient Advisory Board to Advance Access and Representation in Clinical Research

In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $9.73, denoting a -1.12% change from the preceding trading day.

Here's Why Walgreens Boots Alliance (WBA) Fell More Than Broader Market

Dutch Bros

SPDR S&P Regional Banking ETF

Roku

Zoom Video

Merger and acquisitions activity peaked in the United States in 2021, but after SPACs got shellacked and the Biden administration took a harsher view of large-scale mergers, deals became fewer and further between.

5 Merger and Acquisition Targets to Buy Before Trump Takes Over

Walgreens Boots Alliance Inc (NASDAQ:WBA) stock has been in a world of hurt ever since losing its spot on the Dow Jones Industrial Average (DJI) this year.

Why Walgreens Stock's Latest Rally Could Backfire

DEERFIELD, Ill.--(BUSINESS WIRE)--Staying healthy during the holiday season isn't an easy task. According to a recent survey from Walgreens, 47 percent of Americans have missed a holiday event in recent years due to unexpected illness and nearly one in three are worried about it happening again this year. This ‘fear of missing out' (FOMO), and the anxiety it brings, tied to the holiday season is no surprise. Walgreens survey findings indicate Americans are shifting their mindset towards proacti.

Nearly a Third of Americans Worry About Missing a Holiday Event Due to Illness

Celanese

Dollar Tree

Moderna

2024 has been a generally outstanding year for the stock market, with the S&P 500 (^GSPC 0.82%) up by nearly 30% year to date as of Dec. 11. However, not all stocks have performed nearly this well –- in fact, some components of the S&P 500 have underperformed the benchmark index by as much as 90 percentage points.

These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over

If Walgreens Boots Alliance follows through with a sale to private equity, the company might join other healthcare deals under scrutiny for selling out to such investors.

If Walgreens Sells To Private Equity, Deal May Join Others Under Fire

Walgreens surged 18% amid buyout rumors with Sycamore Partners, but the rally may be short-lived as markets cast doubt on the deal's feasibility. History: Walgreens' market cap plummeted from $100 billion in 2015 to $8.44 billion, with recent struggles including a write-down on VillageMD. Sycamore Partners may need partners for the acquisition, reducing deal likelihood; Walgreens could pursue internal plans to improve operations.

How Investors Should Assess The Potential Walgreens Buyout

Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A), the US-based pharmacy giant and owner of Boots, is reportedly in talks to sell itself to Sycamore Partners, a New York private equity firm. According to The Wall Street Journal, the deal could be finalised early next year, raising questions about the future of Boots, the UK's best known high street pharmacy chain.

News for Walgreens Stock (WBA)